Your browser doesn't support javascript.
loading
Bioinspired and biomimetic cancer-cell-derived membrane nanovesicles for preclinical tumor-targeted nanotheranostics.
Prasad, Rajendra; Mendes, Bárbara B; Gorain, Mahadeo; Chandra Kundu, Gopal; Gupta, Narendra; Peng, Berney; Aung Win, Eaint Honey; Qing, He; Conde, João.
Afiliación
  • Prasad R; Department of Mechanical Engineering, Tufts University, Medford, MA, USA.
  • Mendes BB; School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh 221005, India.
  • Gorain M; ToxOmics, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, Lisboa, Portugal.
  • Chandra Kundu G; National Centre for Cell Science, Pune 411007, India.
  • Gupta N; National Centre for Cell Science, Pune 411007, India.
  • Peng B; School of Biotechnology and Kalinga Institute of Medical Sciences (KIMS), KIIT, Institute of Eminence, Bhubaneswar 751024, India.
  • Aung Win EH; Trident Diagnostics Center, Trivenee 302015, India.
  • Qing H; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Conde J; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Cell Rep Phys Sci ; 4(11): 101648, 2023 Nov 15.
Article en En | MEDLINE | ID: mdl-38021344
Bioinspired cell-membrane-camouflaged nanohybrids have been proposed to enhance tumor targeting by harnessing their immune escape and self-recognition abilities. In this study, we introduce cancer-cell-derived membrane nanovesicles (CCMVs) integrated with gold nanorods (AuVNRs) in addition to therapeutic and imaging cargos such as doxorubicin and indocyanine green. This approach enhances targeted tumor imaging and enables synergistic chemo-phototherapeutics for solid tumors. CCMVs demonstrate significant tumor penetration and retention, serving as nanotheranostics with accessible surface biomarkers, biomimicking properties, and homologous targeting abilities. By evading uptake by the mononuclear phagocytic system, CCMVs can diffuse into the deep tumor core, leading to precise tumor reduction while preserving the surrounding healthy tissues. Notably, intravenous administration of these theranostic agents ensures biocompatibility, as evidenced by a survival period of approximately two months (up to 63 days) without any observed side effects. Our findings underscore the diagnostic and therapeutic potential of this biomimetic nanotheranostics platform.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cell Rep Phys Sci Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cell Rep Phys Sci Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos